NRx Pharmaceuticals Statistics
Total Valuation
NRXP has a market cap or net worth of $32.93 million. The enterprise value is $36.87 million.
| Market Cap | 32.93M |
| Enterprise Value | 36.87M |
Important Dates
The next estimated earnings date is Tuesday, May 14, 2024, before market open.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NRXP has 10.49 million shares outstanding. The number of shares has increased by 15.20% in one year.
| Shares Outstanding | 10.49M |
| Shares Change (YoY) | +15.20% |
| Shares Change (QoQ) | -1.52% |
| Owned by Insiders (%) | 27.41% |
| Owned by Institutions (%) | 3.91% |
| Float | 6.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.36
| Current Ratio | 0.36 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -250.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -194.50% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$15.08M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.93% in the last 52 weeks. The beta is 1.03, so NRXP's price volatility has been similar to the market average.
| Beta (1Y) | 1.03 |
| 52-Week Price Change | -48.93% |
| 50-Day Moving Average | 4.73 |
| 200-Day Moving Average | 3.77 |
| Relative Strength Index (RSI) | 34.36 |
| Average Volume (30 Days) | 212,827 |
Short Selling Information
The latest short interest is 4.25 million, so 40.48% of the outstanding shares have been sold short.
| Short Interest | 4.25M |
| Short Previous Month | 3.71M |
| Short % of Shares Out | 40.48% |
| Short % of Float | 61.73% |
| Short Ratio (days to cover) | 2.43 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.84M |
| Pretax Income | -30.15M |
| Net Income | -30.16M |
| EBITDA | -30.03M |
| EBIT | -30.03M |
| Earnings Per Share (EPS) | -$4.00 |
Balance Sheet
The company has $4.60 million in cash and $9.16 million in debt, giving a net cash position of -$4.57 million or -$0.44 per share.
| Cash & Cash Equivalents | 4.60M |
| Total Debt | 9.16M |
| Net Cash | -4.57M |
| Net Cash Per Share | -$0.44 |
| Equity / Book Value | -11.73M |
| Book Value Per Share | -1.12 |
| Working Capital | -12.16M |
Cash Flow
In the last 12 months, operating cash flow was -$21.66 million and capital expenditures -$3,000, giving a free cash flow of -$21.66 million.
| Operating Cash Flow | -21.66M |
| Capital Expenditures | -3,000 |
| Free Cash Flow | -21.66M |
| FCF Per Share | -$2.86 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.20% |
| Shareholder Yield | -15.20% |
| Earnings Yield | -93.36% |
| FCF Yield | -67.05% |
Analyst Forecast
The average price target for NRXP is $20.00, which is 536.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 536.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 2, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 2, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |